Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SPECTRUM PHARMACEUTICALS, INC.

(SPPI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Spectrum Pharmaceuticals : SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit

10/06/2021 | 11:01am EST

LOS ANGELES, Oct. 6, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)

Class Period: December 27, 2018 - August 5, 2021
Lead Plaintiff Deadline: November 1, 2021

If you wish to serve as lead plaintiff of the Spectrum lawsuit, you can submit your contact information at https://www.glancylaw.com/cases/spectrum-pharmaceuticals-inc-1/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

The complaint alleges that, throughout the Class Period, Defendants failed to disclose to investors: (1) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (2) the foregoing deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form; (3) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision
View original content:https://www.prnewswire.com/news-releases/sppi-investors-have-opportunity-to-lead-spectrum-pharmaceuticals-inc-securities-fraud-lawsuit-301393767.html

SOURCE Glancy Prongay & Murray LLP


© PRNewswire 2021
All news about SPECTRUM PHARMACEUTICALS, INC.
12/06SPECTRUM PHARMACEUTICALS : Current Corporate Presentation
PU
12/06Spectrum Pharmaceuticals Submits New Drug Application for Poziotinib to US Food and Dru..
MT
12/06Spectrum Pharmaceuticals Submits New Drug Application for Poziotinib
BU
12/03SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
12/01Spectrum Pharmaceuticals CEO Agrees to Retire, COO Named Successor From Dec. 31
MT
12/01Spectrum Pharmaceuticals Announces Changes to Management Team and Board of Directors
BU
12/01Spectrum Pharmaceuticals, Inc. Announces Appointment of Tom Riga as President and CEO, ..
CI
12/01Spectrum Pharmaceuticals, Inc. Announces Changes to Board of Directors
CI
11/30Spectrum Pharmaceuticals to Participate in JMP Securities Hematology and Oncology Summi..
BU
11/11Spectrum Pharmaceuticals to Participate in 2021 Jefferies London Healthcare Conference
BU
More news
Analyst Recommendations on SPECTRUM PHARMACEUTICALS, INC.
More recommendations